Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor
BCL11B 转录因子对 CD4 T 细胞发育和功能的调节
基本信息
- 批准号:7760538
- 负责人:
- 金额:$ 23.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-03-01 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AttenuatedAutoimmune DiseasesBiochemicalCD4 Positive T LymphocytesCessation of lifeColitisExcisionFailureGene ExpressionGenerationsImmune responseMature T-LymphocyteMolecularMusNamesPeptide/MHC ComplexPeripheralPhenotypePlayPrincipal InvestigatorProcessRegulationRegulatory T-LymphocyteResearchRoleSignal TransductionSpecificityStagingStreamSystemT-Cell DevelopmentT-LymphocyteThymic epithelial cellTranscriptional RegulationWasting Syndromeimmune functionneglectprogramspublic health relevancethymocytetranscription factor
项目摘要
DESCRIPTION (provided by applicant): The fate of double positive thymocytes is dictated by the strength and duration of the interaction between TCR and self peptide-MHC complex presented on the cortical thymic epithelial cells. A weak interaction results in positive selection and survival signals which rescue DP thymocytes from death by neglect. Positive selection is critical for immune function, as this is the process by which a repertoire of T cells bearing useful TCR specificities is produce. However little is known about the transcriptional control of positive selection. We found that the transcription factor BCL11B controls early steps of positive selection, as removal results in attenuated TCR signaling and failure of positive selection. In addition, in the absence of BCL11B DP thymocytes have reduced survival even in the absence of TCR signaling, demonstrating that BCL11B is a major player in the control of survival of DP thymocytes. Supporting our hypothesis that BCL11B is critical for positive selection and survival of DP thymocytes we have evidence that BCL11B controls expression of genes associated with positive selection and survival of DP thymocytes. In addition, in the absence of BCL11B starting with DP stage of T cell development the reduced number of peripheral BCL11B-deficient T lymphocytes present an activated phenotype and mice develop wasting disease and colitis. Conditional removal of BCL11B in mature T cells also results in increased number of activated CD4+ T cells. These results support the hypothesis that BCL11B regulates mature CD4+ T lymphocytes. Using conditional and inducible mouse system and biochemical studies we propose to investigate the mechanisms by which BCL11B controls positive selection and survival of DP thymocytes through transcriptional control of gene expression. In addition we propose to determine the role of BCL11B in conventional and T regulatory CD4+ T cells. Public Health Relevance Statement: The results of these studies will contribute significantly to a molecular understanding of positive selection and survival of DP thymocytes, which both play a crucial role in generation of the appropriate T cells for an adequate immune response. In addition, these studies will contribute to understanding transcriptional program of effector CD4+ T and CD4+ T regulatory cells, and have important implications for autoimmune diseases.
描述(由申请方提供):双阳性胸腺细胞的命运取决于皮质胸腺上皮细胞上呈递的TCR和自身肽-MHC复合物之间相互作用的强度和持续时间。弱相互作用导致正选择和存活信号,其将DP胸腺细胞从忽视死亡中拯救出来。正选择对于免疫功能是至关重要的,因为这是产生具有有用的TCR特异性的T细胞库的过程。然而,很少有人知道的转录控制的积极选择。我们发现转录因子BCL 11B控制正选择的早期步骤,因为去除导致TCR信号传导减弱和正选择失败。此外,在不存在BCL 11B的情况下,DP胸腺细胞即使在不存在TCR信号传导的情况下也具有降低的存活率,表明BCL 11B是控制DP胸腺细胞存活的主要参与者。支持我们的假设,BCL 11 B是DP胸腺细胞的阳性选择和生存的关键,我们有证据表明,BCL 11 B控制与阳性选择和DP胸腺细胞的生存相关的基因的表达。此外,在从T细胞发育的DP阶段开始不存在BCL 11B的情况下,外周BCL 11B缺陷型T淋巴细胞的数量减少,呈现活化的表型,并且小鼠发展为消耗性疾病和结肠炎。在成熟T细胞中有条件地去除BCL 11B也导致活化的CD 4 + T细胞的数量增加。这些结果支持BCL 11B调节成熟的CD 4 + T淋巴细胞的假设。使用条件和诱导小鼠系统和生化研究,我们建议调查的机制,BCL 11 B控制阳性选择和DP胸腺细胞的生存通过转录控制基因表达。此外,我们建议确定BCL 11 B在常规和T调节性CD 4 + T细胞中的作用。公共卫生相关性声明:这些研究的结果将有助于显着的DP胸腺细胞,这两者都发挥了至关重要的作用,在产生适当的T细胞,充分的免疫反应的积极选择和生存的分子理解。此外,这些研究将有助于理解效应性CD 4 + T细胞和CD 4 + T调节细胞的转录程序,并对自身免疫性疾病具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dorina Avram其他文献
Dorina Avram的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dorina Avram', 18)}}的其他基金
Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis
组织锚定与循环工程酶构建体用于银屑病免疫代谢解决
- 批准号:
10667165 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
高通量筛选分析,鉴定针对 Hectd3 的化学探针,Hectd3 是一种与多发性硬化症有关的 E3 泛素连接酶
- 批准号:
10391539 - 财政年份:2021
- 资助金额:
$ 23.46万 - 项目类别:
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
高通量筛选分析,鉴定针对 Hectd3 的化学探针,Hectd3 是一种与多发性硬化症有关的 E3 泛素连接酶
- 批准号:
10597043 - 财政年份:2021
- 资助金额:
$ 23.46万 - 项目类别:
Tolerogenic dual microparticle system for treatment of multiple sclerosis
用于治疗多发性硬化症的致耐受性双微粒系统
- 批准号:
9918870 - 财政年份:2017
- 资助金额:
$ 23.46万 - 项目类别:
Transcriptional control in innate lymphoid type II cells
先天淋巴细胞 II 型细胞的转录控制
- 批准号:
8732115 - 财政年份:2014
- 资助金额:
$ 23.46万 - 项目类别:
Transcriptional control in innate lymphoid type II cells
先天淋巴细胞 II 型细胞的转录控制
- 批准号:
8853814 - 财政年份:2014
- 资助金额:
$ 23.46万 - 项目类别:
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor
BCL11B 转录因子对 CD4 T 细胞发育和功能的调节
- 批准号:
8021853 - 财政年份:2008
- 资助金额:
$ 23.46万 - 项目类别:
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor
BCL11B 转录因子对 CD4 T 细胞发育和功能的调节
- 批准号:
7437569 - 财政年份:2008
- 资助金额:
$ 23.46万 - 项目类别:
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor
BCL11B 转录因子对 CD4 T 细胞发育和功能的调节
- 批准号:
8213720 - 财政年份:2008
- 资助金额:
$ 23.46万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 23.46万 - 项目类别: